Search
Oxatomide
go.drugbank.com/drugs/DB12877ApprovedOxatomide has been used in trials studying the treatment of Muscular Dystrophy, Duchenne.
Categories: Antihistamines for Systemic UseDosulepin
go.drugbank.com/drugs/DB09167ApprovedInvestigationalIts hydrochloride form is a common active ingredient in different drug formulations. … The use of dosulepsin is only recommended in patients who are intolerant or unresponsive to alternative antidepressant therapies.
Tranylcypromine
go.drugbank.com/drugs/DB00752ApprovedInvestigationalA propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and p...
Categories: Antidepressive Agents Indicated for Depression, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesR450
go.drugbank.com/drugs/DB05469ExperimentalIt is being considered for treatment of stress-related urinary incontinence. … Phase IIa data for the drug show it reduced the number of incontinent episodes compared to placebo with minimal cardiovascular effects.
Lumefantrine co-artemether
go.drugbank.com/drugs/DB13085ApprovedInvestigationalWithdrawnLumefantrine Co-Artemether (Riamet) has been investigated for the treatment of Malaria, Malaria, Falciparum, Malaria in Pregnancy, Uncomplicated Malaria, and Uncomplicated Knowlesi Malaria. … The exact mechanism of action of lumefantrine is not well defined, but it is thought to inhibit -hematin formation, an important detoxification pathway for the parasite.
2-deoxyglucose
go.drugbank.com/drugs/DB08831InvestigationalAlthough there are several possible therapeutic indications for 2-deoxyglucose, presently there is no approved indication for 2-deoxyglucose as a therapeutic agent. … 2-deoxyglucose is predominantly used as a diagnostic agent in its radiolabelled form (fluorine-18 is used as the radiolabel).
FK352B
go.drugbank.com/drugs/DB06484ExperimentalFK352B is a adenosine A1 antagonist that is developed for the treatment of dialysis-induced hypotension.
AER001
go.drugbank.com/drugs/DB05078InvestigationalAER001, an IL4/13 receptor antagonist for severe asthma and eczema currently in Phase 2 studies.
GC-373
go.drugbank.com/drugs/DB15797ExperimentalThe results showed potent inhibition of the target, suggesting that GC-373 holds therapeutic potential for Covid-19[A219036].
Categories: Experimental Unapproved Treatments for COVID-19Meprednisone
go.drugbank.com/drugs/DB09383ApprovedCategories: Corticosteroids for Systemic Use, Corticosteroids for Systemic Use, Plain